Tasuku Honjo (born 1942) is a Japanese immunologist whose laboratory discoveries reshaped modern understanding of immune regulation and enabled a new class of cancer treatments. Honjo identified several molecules that control how immune cells communicate and mutate, most notably the protein known as programmed cell death protein 1 (PD‑1). His work spans fundamental studies of cytokines, enzymes that diversify antibodies, and inhibitory receptors that restrain immune responses.

Key discoveries

Honjo and his colleagues made multiple influential findings that are widely cited in immunology and medicine. Major contributions include:

  • Identification and naming of PD‑1, an inhibitory receptor on T cells that downregulates immune activity when engaged by its ligands.
  • Discovery and characterization of cytokines such as interleukin‑4 (IL‑4) and interleukin‑5 (IL‑5), which help define T helper cell functions and influence antibody production and allergic responses.
  • Discovery of activation‑induced cytidine deaminase (AID), an enzyme essential for somatic hypermutation and class‑switch recombination that generate antibody diversity.

How his findings fit together

These discoveries illuminate different layers of immune regulation. Cytokines like IL‑4 and IL‑5 are signaling proteins that guide the development and behavior of immune cells. AID is a molecular machine inside B cells that intentionally alters antibody genes to improve pathogen recognition. PD‑1 operates on T cells as a checkpoint that limits immune activation to prevent excessive inflammation or autoimmunity. Together, such regulators explain how the immune system balances effective defense with self‑control.

Impact on cancer therapy

The identification of PD‑1 provided the conceptual basis for so‑called immune checkpoint blockade: the therapeutic interruption of inhibitory signals to unleash anti‑tumor T cells. Translating this concept into drugs produced a new class of immunotherapies that have produced durable remissions in several cancers. These treatments, developed by multiple research teams and pharmaceutical efforts worldwide, illustrate how a molecular discovery in basic biology can become a transformative clinical approach.

Recognition and influence

Honjo's contributions have been recognized by major scientific societies and prizes. He was elected to international academies and, in 2018, shared the Nobel Prize in Physiology or Medicine with James P. Allison for discoveries leading to cancer immunotherapy. More details on his membership in scientific bodies can be found via academy profiles, and his Nobel recognition is summarized at the Nobel citation.

Beyond awards, Honjo's work continues to influence research on autoimmunity, infectious disease, and therapeutic design. His discoveries remain cornerstones of immunology courses and ongoing investigations into how to modulate immune responses more precisely. The practical and conceptual legacy of his research illustrates the close interplay between molecular biology, translational science, and clinical medicine.